Thursday, October 03, 2013 2:05:00 PM
Source: Tom Meyer, Wall St. Cheat Sheet (10/1/13)
3 Small-Cap Biotechnology Stocks Making Big MovesSource: Tom Meyer, Wall St. Cheat Sheet (10/1/13)
"Investors have seen a tremendous rally in the biotechnology industry. Many stocks have been participating in the rally, but there have been a few that are especially standing out because of performance and/or new announcements."
During the past few weeks, investors have seen a tremendous rally in the biotechnology industry. Many stocks have been participating in the rally, but there have been a few that are especially standing out because of performance and/or new announcements.
Celldex Therapeutics (NASDAQ:CLDX) appears to have traded into another stratosphere. Since Sept. 20, the stock has appreciated by more than 25%. With a lot of positive press coming out about the company's pipeline, investors appear to be big believers in the company's eventual ability to treat a variety of cancer indications. Of particular importance is CDX-011, an antibody-drug conjugate that targets glycoprotein NMB (GPNMB). GPNMB is a protein overexpressed by multiple tumor types, including breast cancer and melanoma. In late 2012, the company completed a Phase 2 EMERGE study in metastatic breast cancer. The final results supported overall survival benefit in patients with high GPNMB expression.
On Sept. 23, analyst Howard Liang from Leerink Swann raised his price target for Celldex to $45. Mr. Liang expects positive updates from the company at the upcoming Society for Immunotherapy of Cancer meeting on Nov. 7. While Celldex appears to have some incredible trading momentum, investors may want to be wary of the current market capitalization, which values the company at over $3 billion. Investors looking for a cheaper play in the breast cancer space may want to consider a smaller competitor called Medifocus (OTC:MDFZF).
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM